Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848630 | 1.00 | NAAA (0.55) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL8816700 | 1.00 | NAAA (0.55) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL4852360 | 1.00 | NAAA (0.55) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL4853286 | 1.00 | NAAA (0.55) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL696797 | 0.98 | NAAA (0.52) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL696985 | 0.91 | ALDH1A1 (0.54) | NAAATSHREPHX1HCAR2ALDH1A1 | |
| SCHEMBL4934658 | 0.89 | NAAA (0.67) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL1834574 | 0.89 | NAAA (0.67) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL1841329 | 0.89 | NAAA (0.67) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL1839498 | 0.89 | NAAA (0.67) | NAAATSHREPHX1HCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378548-B2 | Tertiary amine compounds having an ester structure and processes for preparing the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | claimed |
| US-20060217570-A1 | Novel Tertiary Amine Compounds Having An Ester Structure And Processes For Preparing The Same | SHIN-ETSU CHEMICAL CO., LTD. | 2006-09-28 | — | — | US | claimed |
| CN-118109069-A | Resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108899-A | Curable resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214126-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-10-28 | — | — | WO | disclosed |
| CN-109336891-B | 5- (furan-2' -carbonyl) -2, 3-dihydro-1H-pyrrolizine-7-carboxylic acid and derivatives thereof | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2020-04-10 | — | — | CN | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-2320732-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | Pfizer Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7829580-B2 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-5459148-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0573218-A2 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5073551-A | Antibiotics | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0335390-A2 | Novel cephalosporin compounds | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-10-04 | — | — | EP | disclosed |
| US-4496562-A | 7-Substituted-3-cephem-4-carboxylic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217570-A1 | Novel Tertiary Amine Compounds Having An Ester Structure And Processes For Preparing The Same | HRH3, HRH4, HRH2 | NAAA 5/4885TSHR 2088/4885EPHX1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.